Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» liver cancer
liver cancer
Celsion craters 65% on dim hopes for ThermoDox in liver cancer
Celsion craters 65% on dim hopes for ThermoDox in liver cancer
Seeking Alpha
Celsion
liver cancer
ThermoDox
clinical trials
Flag link:
Roche nabs frontline OK for Avastin/Tecentriq in common liver cancer, besting an old Bayer drug
Roche nabs frontline OK for Avastin/Tecentriq in common liver cancer, besting an old Bayer drug
Endpoints
Roche
Avastin
Tecentriq
metastatic hepatocellular carcinoma
liver cancer
FDA
Flag link:
ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data
ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data
Fierce Pharma
Merck
Eisai
liver cancer
ASCO 2020
Keytrua
Lenvima
clinical trials
Flag link:
ASCO: Has AstraZeneca finally found a place for long-plagued I-O candidate tremelimumab?
ASCO: Has AstraZeneca finally found a place for long-plagued I-O candidate tremelimumab?
Fierce Pharma
AstraZeneca
ASCO 2020
clinical trials
tremelimumab
liver cancer
Imfinzi
Flag link:
Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo
Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo
Fierce Pharma
Bristol-Myers Squibb
Opdivo
Yervoy
FDA
liver cancer
hepatocellular carcinoma
Flag link:
Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer
Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer
Endpoints
Roche
Tecentriq
Avastin
liver cancer
China
Bayer
Nexavar
clinical trials
Flag link:
Breakthrough status and promise of a speedy review arrives for Opdivo/Yervoy combination as Bristol-Myers bites at Bayer
Breakthrough status and promise of a speedy review arrives for Opdivo/Yervoy combination as Bristol-Myers bites at Bayer
Endpoints
Bristol-Myers Squibb
Opdivo
liver cancer
Yervoy
FDA
Flag link:
Roche's Tecentriq scores a first-in-class double win in new liver cancer patients
Roche's Tecentriq scores a first-in-class double win in new liver cancer patients
Fierce Pharma
Roche
liver cancer
Tecentriq
immuno-oncology
Avastin
Nexavar
Flag link:
Exelixis Hits Blockbuster Status
Exelixis Hits Blockbuster Status
Motley Fool
Exelixis
cabozantinib
Cabometx
kidney cancer
liver cancer
Cometriq
thyroid cancer
Flag link:
Bristol-Myers star Opdivo fails survival test in a matchup with Nexavar aimed at shaking up the big HCC market
Bristol-Myers star Opdivo fails survival test in a matchup with Nexavar aimed at shaking up the big HCC market
Endpoints
Bristol-Myers Squibb
Opdivo
Bayer
Nexavar
liver cancer
clinical trials
Flag link:
Lilly gets fifth use for Cyramza with FDA liver cancer nod
Lilly gets fifth use for Cyramza with FDA liver cancer nod
Pharmaforum
Eli Lilly
Cyramza
FDA
liver cancer
hepatocellular carcinoma
Flag link:
After a delay, Can-Fite digs into subpopulation data as liver cancer drug fails to hit primary endpoint
After a delay, Can-Fite digs into subpopulation data as liver cancer drug fails to hit primary endpoint
Fierce Biotech
Can-Fite BioPharma
liver cancer
namodenoson
clinical trials
Flag link:
Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it the green light
Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it the green light
Endpoints
Merck
Keytruda
clinical trials
liver cancer
Flag link:
Anti-rejection drug rapamycin shows promise in liver cancer
Anti-rejection drug rapamycin shows promise in liver cancer
Fierce Biotech
liver cancer
mTOR inhibitors
rapamycin
Flag link:
FDA approves Cabometyx for liver cancer
FDA approves Cabometyx for liver cancer
BioCentury
Exelixis
Ipsen
Cabometyx
liver cancer
FDA
Flag link:
Merck gets FDA okay for Keytruda as liver cancer therapy
Merck gets FDA okay for Keytruda as liver cancer therapy
Pharmaforum
Merck
Keytruda
FDA
hepatocellular carcinoma
liver cancer
Flag link:
Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma
Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma
CP Wire
China
Eisai
Merck
Lenvima
liver cancer
HCC
Flag link:
Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma
Eisai
Merck
Lenvima
liver cancer
hepatocellular carcinoma
Flag link:
Death rate from liver cancer skyrockets
Death rate from liver cancer skyrockets
WWSB
liver cancer
CDC
Flag link:
Japan's Eisai sets price tag of about $16,000 on liver cancer drug
Japan's Eisai sets price tag of about $16,000 on liver cancer drug
Yahoo/Reuters
Eisai
liver cancer
drug pricing
Lenvima
Flag link:
Pages
1
2
3
4
next ›
last »